A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
Public ClinicalTrials.gov record NCT01426789. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension
Study identification
- NCT ID
- NCT01426789
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Enrollment
- 100 participants
Conditions and interventions
Conditions
Interventions
- Placebo Drug
- Secukinumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2011
- Primary completion
- Jan 31, 2014
- Completion
- Jan 31, 2014
- Last update posted
- Aug 9, 2015
2011 – 2014
United States locations
- U.S. sites
- 16
- U.S. states
- 10
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis Investigative Site | Phoenix | Arizona | 85023 | — |
| Novartis Investigative Site | Tuscon | Arizona | 85724 | — |
| Novartis Investigative Site | Anahiem | California | 92804 | — |
| Novartis Investigative Site | Clearwater | Florida | 33756 | — |
| Novartis Investigative Site | Coral Gables | Florida | 33134 | — |
| Novartis Investigative Site | Fleming Island | Florida | 32003 | — |
| Novartis Investigative Site | Miami | Florida | 33143 | — |
| Novartis Investigative Site | Pinellas Park | Florida | 33781 | — |
| Novartis Investigative Site | Venice | Florida | 34292 | — |
| Novartis Investigative Site | Marietta | Georgia | 30060 | — |
| Novartis Investigative Site | South Bend | Indiana | 46601 | — |
| Novartis Investigative Site | Springfield | Missouri | 65807 | — |
| Novartis Investigative Site | Albuquerque | New Mexico | 87102 | — |
| Novartis Investigative Site | Statesville | North Carolina | 28625 | — |
| Novartis Investigative Site | Oklahoma City | Oklahoma | 73112 | — |
| Novartis Investigative Site | San Antonio | Texas | 78217 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01426789, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 9, 2015 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01426789 live on ClinicalTrials.gov.